ABSI — Absci Corporation Stock Price, Chart & AI Report

Neutral Oct 29, 2025 • 20:05 UTC Benzinga • Globe Newswire

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

Absci, a clinical-stage biotech company using generative AI for drug discovery, will report its Q3 2025 financial and operating results on November 12, 2025, via a webcast conference call.

ABSI biotech AI drug discovery financial results generative AI

Sentiment note

The article is a standard financial reporting announcement without strong positive or negative indicators, simply providing information about an upcoming earnings report

Positive Oct 27, 2025 • 12:00 UTC GlobeNewswire Inc. • Absci Corporation

Absci to Participate in Upcoming Investor Conferences

Absci Corporation announced participation in upcoming healthcare investor conferences and plans to host a key opinion leader (KOL) seminar on its ABS-201 hair regrowth program, with an accelerated Phase 1/2a trial expected to begin in December 2025.

ABSI JEF biotech AI drug discovery generative AI hair regrowth androgenetic alopecia

Sentiment note

Company is advancing innovative AI-driven drug discovery platform, accelerating clinical trials, and presenting at multiple prestigious healthcare conferences

Positive Oct 14, 2025 • 15:41 UTC Investing.com • Nathan Reiff

Absci Stock Offers High-Risk AI Biotech Exposure With 110% Upside Forecast

Absci Corp, a small AI biotech company, offers high-risk investment potential in drug discovery using generative AI, with multiple drug candidates in clinical trials and strategic partnerships with major pharma companies.

ABSI MRK ALMRY RXRX AI biotechnology drug discovery generative AI

Sentiment note

Company has promising AI drug discovery platform, strategic partnerships with Merck and Almirall, multiple drug candidates in trials, and analysts forecast 110% upside potential

Positive Oct 9, 2025 • 15:00 UTC GlobeNewswire Inc. • Towards Healthcare

Computer-Aided Drug Design (CADD) Market Competitive Landscape Report – Towards Healthcare

The global CADD market is experiencing rapid growth, projected to generate substantial revenue between 2025-2034, driven by technological innovations, AI integration, and increasing demand across pharmaceutical and research sectors.

ABSI drug discovery AI machine learning computational drug design biotechnology

Sentiment note

Collaborated with AMD to deploy AI accelerators for drug discovery workloads

Positive Sep 11, 2025 • 16:10 UTC Benzinga • Vandana Singh

Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration

Absci partnered with Oracle Cloud Infrastructure and AMD to accelerate AI-driven drug discovery, leveraging high-performance computing infrastructure for molecular simulations and antibody design.

ABSI ORCL AMD AI drug discovery molecular simulation cloud infrastructure biotechnology

Sentiment note

Company is advancing its AI drug discovery platform through strategic technological collaboration

Positive Aug 20, 2025 • 12:00 UTC GlobeNewswire Inc. • Absci Corporation

Absci to Participate in Upcoming Investor Conferences

Absci Corporation announced participation in upcoming healthcare investor conferences and highlighted its AI-driven drug discovery platform, focusing on innovative therapeutics like ABS-101 for inflammatory bowel disease and ABS-201 for hair regrowth.

ABSI ALMRY AI drug discovery biologics healthcare conferences therapeutic innovation

Sentiment note

Company is expanding collaborations, strengthening its balance sheet, and advancing innovative AI-driven drug discovery platform with multiple therapeutic candidates

Positive Jul 30, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight

The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.

ABCL ABSI TWST TMO antibody discovery biologics monoclonal antibodies therapeutic development

Sentiment note

Mentioned in strategic partnership with Twist Bioscience, demonstrating technological innovation in AI-based antibody design

Neutral Jul 25, 2025 • 00:45 UTC Benzinga • Globe Newswire

Absci Announces Pricing of Public Offering of Common Stock

Absci Corporation announced a public offering of 16,670,000 shares of common stock at $3.00 per share, expecting to raise approximately $50 million to fund drug development programs and corporate purposes.

ABSI MS MSPA MSPE public offering stock biopharmaceutical generative AI

Sentiment note

The company is raising capital through a standard public offering, which indicates a strategic financial move to fund ongoing research and development without significant positive or negative implications

Neutral Jul 25, 2025 • 00:45 UTC GlobeNewswire Inc. • Absci Corporation

Absci Announces Pricing of Public Offering of Common Stock

Absci Corporation plans to raise approximately $50 million through a public offering of 16,670,000 shares at $3.00 per share, with underwriters having an option to purchase additional shares. The proceeds will fund drug development programs and corporate initiatives.

ABSI MS MSPA MSPE public offering stock sale biopharmaceutical generative AI

Sentiment note

The company is conducting a standard public offering to raise capital for ongoing research and development, which indicates a typical financial strategy without strong positive or negative implications

Neutral Jul 24, 2025 • 20:54 UTC GlobeNewswire Inc. • Absci Corporation

Absci Announces Proposed Public Offering of Common Stock

Absci Corporation plans to raise $50 million through a public stock offering, with potential additional $7.5 million from underwriters. Proceeds will fund drug development programs and corporate initiatives.

ABSI MS MSPA MSPE public offering stock sale biopharmaceutical generative AI

Sentiment note

The company is seeking standard capital funding through a public stock offering, which is a typical financial strategy for growth-stage companies. The neutral sentiment reflects a routine financial transaction without significant positive or negative implications.

Positive Mar 4, 2025 • 21:00 UTC GlobeNewswire Inc. • N/A

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci Corporation, a data-first generative AI drug creation company, announced that it granted a non-statutory stock option to a newly-hired non-executive employee as an inducement to join the company.

ABSI Absci Corporation stock option inducement new employee

Sentiment note

The article announces that Absci Corporation granted a stock option to a new employee, which is a positive sign of the company's growth and ability to attract talent.

Positive Jan 22, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Absci Corporation, a data-first generative AI drug creation company, announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference, where the company's management will be featured in a fireside chat.

ABSI Absci Corporation Guggenheim Securities SMID Cap Biotech Conference

Sentiment note

The article highlights Absci's participation in an industry conference, which suggests the company is actively engaged in its business activities and seeking to engage with investors and the broader biotech community.